更新于：2024-11-05
Acetaminophen
对乙酰氨基酚
更新于：2024-11-05
概要
基本信息
简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准， 它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛 与阿片类药物联用，或对抗发烧。 它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂 片剂、注射剂和栓剂。 虽然主要是口服给药，但也可以静脉内给药。 重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。 服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于 无需处方即可广泛使用 处方药或作为处方药。 |
药物类型 小分子化药 |
别名 4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL + [89] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
关联
1,413
项与 对乙酰氨基酚 相关的临床试验Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids (CARES for Kids) Trial
Intravenous Acetaminophen for Postoperative Delirium in Older Patients Recovering From Major Noncardiac Surgery: a Randomised Controlled Study
Evaluation of the effect of intravenous acetaminophen on opioid consumption and pain control after coronary artery bypass surgery
100 项与 对乙酰氨基酚 相关的临床结果
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的转化医学
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的专利（医药）
登录后查看更多信息
29,095
项与 对乙酰氨基酚 相关的文献（医药）2025-01-01Journal of Clinical and Experimental Hepatology
Adverse Events and Outcomes of High-volume Plasma Exchange in 50 Acute Liver Failure Patients: A Monocentric Retrospective Real-world Study
Article
作者: Quelven, Quentin ; Coirier, Valentin ; Rayar, Michel ; Houssel-Debry, Pauline ; Gacouin, Arnaud ; Camus, Christophe ; Painvin, Benoît ; Grulois, Isabelle ; Maamar, Adel ; Lesouhaitier, Mathieu ; Terzi, Nicolas ; Delamaire, Flora ; Tadié, Jean-Marc ; Guillot, Pauline
Background and aims:
Acute liver failure (ALF) is a condition that mostly requires Intensive Care Unit (ICU) admission and sometimes necessitates emergency liver transplantation. High-volume plasma exchange (HVPE) may improve transplant-free survival (TFS) in ALF. Our study assessed complications of HVPE therapy and outcome in ALF patients.
Methods:
We conducted a single-center retrospective study of all patients admitted to the ICU for ALF and who underwent HVPE between June 2016 and June 2021. The plasmapheresis technique used was centrifugation, and the volume exchanged was calculated as 15% of the ideal body weight. Dedicated staff prospectively collected clinical adverse effects, while biological data were retrospectively collected. The primary outcome was the rate of severe adverse effects (SAE, defined as severe manifestations of hypotension, allergy, metabolic disturbances or other life-threatening event) that occurred during HVPE sessions. Factors influencing day-21 TFS were also studied.
Results:
One hundred twenty sessions were performed in 50 patients. The main etiology for ALF was paracetamol (52% of the patients). During the session, hemoglobin, platelet, transaminases, ammonia and bilirubin decreased, coagulation factors increased, and creatinine and lactate remained unchanged. At least one SAE was reported for 32 out of 120 sessions (26.7% [19%-35.5%], mostly severe alkalosis [24/117], hypotension [4/120] and hypocalcemia [4/119]). Arterial pH ≤ 7.43 following HVPE and paracetamol etiology were negatively and positively associated with day-21 TFS, respectively.
Conclusion:
Severe adverse effects were frequent during HVPE performed for ALF, mainly severe alkalosis, hypotension and hypocalcemia. Post-HVPE, pH and paracetamol etiology were prognosis markers.
2025-01-01Journal of Environmental Sciences
A review on reactive oxygen species-induced mechanism pathways of pharmaceutical waste degradation: Acetaminophen as a drug waste model
Review
作者: Humayun, Saba ; Hayyan, Maan ; Alias, Yatimah
Innately designed to induce physiological changes, pharmaceuticals are foreknowingly hazardous to the ecosystem. Advanced oxidation processes (AOPs) are recognized as a set of contemporary and highly efficient methods being used as a contrivance for the removal of pharmaceutical residues. Since reactive oxygen species (ROS) are formed in these processes to interact and contribute directly toward the oxidation of target contaminant(s), a profound insight regarding the mechanisms of ROS leading to the degradation of pharmaceuticals is fundamentally significant. The conceptualization of some specific reaction mechanisms allows the design of an effective and safe degradation process that can empirically reduce the environmental impact of the micropollutants. This review mainly deliberates the mechanistic reaction pathways for ROS-mediated degradation of pharmaceuticals often leading to complete mineralization, with a focus on acetaminophen as a drug waste model.
2024-12-31Renal failure
Magnesium hydride protects against acetaminophen-induced acute kidney injury by inhibiting TXNIP/NLRP3/nf-κb pathway
Article
作者: Liu, Su ; Si, Yachen ; Zhao, Tingting ; Zhang, Yinyin ; Cheng, Jin ; Lu, Hongtao ; Li, Hongxia ; Sun, Xuejun ; Liu, Lulu
Acetaminophen (APAP)-induced acute kidney injury (APAP-AKI) has turned into one of reasons for clinic obtained renal insufficiency. Magnesium hydride (MgH2), as a solid-state hydrogen source, might be potentially applied in clinical practice. The current study aimed to investigate the protective effect of MgH2 against APAP-AKI. The results showed that MgH2 improved renal function and histological injury in mice of APAP-AKI. MgH2 also had protective effects on APAP-induced cytotoxicity in HK-2 cells. In addition, the increased level of reactive oxygen species (ROS) and expressions of inflammatory cytokines (TNF-α and IL-1β) and pro-apoptotic factors (Bad, Bax, Caspase3, and CytC) induced by APAP were downregulated with MgH2 treatment. Furthermore, the expressions of molecules related to TXNIP/NLRP3/NF-κB pathway (TXNIP, NLRP3, NF-κB p65 and p-NF-κB p65) in renal tissues and HK-2 cells were enhanced by APAP overdose, which were reduced by MgH2 administration. Collectively, this study indicated that MgH2 protects against APAP-AKI by alleviating oxidative stress, inflammation and apoptosis via inhibition of TXNIP/NLRP3/NF-κB signaling pathway.
100 项与 对乙酰氨基酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头痛 | 美国 | 1978-02-09 | |
| 镇痛 | 日本 | 1966-07-01 | |
| 发热 | 中国 | 1966-01-01 | |
| 疼痛 | 中国 | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | - | 2017-02-01 | |
| 骨关节炎 | 临床3期 | 美国 | 2015-01-01 | |
| 发作性紧张型头痛 | 临床3期 | 美国 | 2013-04-01 | |
| 急性疼痛 | 临床3期 | 美国 | 2008-01-01 | |
| 子宫癌 | 临床3期 | 美国 | 2006-11-01 | |
| 急性偏头痛 | 临床3期 | 美国 | 2006-03-01 | |
| 髋关节炎 | 临床3期 | - | 2005-10-18 | |
| 糖尿病性神经病变 | 临床3期 | - | 2003-12-01 | |
| 痛性神经病变 | 临床3期 | - | 2003-12-01 | |
| 术后疼痛 | 临床3期 | - | 2002-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 488 | (IV Acetaminophen-Active) | 鹹遞繭築構憲願顧壓淵(淵遞夢築範願夢簾顧選) = 夢簾獵淵蓋襯餘壓鏇鑰 鬱構襯簾範淵網夢鹽簾 (鹹鹹繭遞膚憲遞鏇蓋艱, 範糧顧範顧築鬱艱製繭 ~ 簾範襯襯醖製選窪範衊) 更多 | - | 2024-09-27 | ||
(IV Vitamin C-Active) | 鹹遞繭築構憲願顧壓淵(淵遞夢築範願夢簾顧選) = 憲餘鏇獵廠範簾鑰構壓 鬱構襯簾範淵網夢鹽簾 (鹹鹹繭遞膚憲遞鏇蓋艱, 觸憲餘淵網範淵網膚憲 ~ 積簾獵鬱壓蓋醖觸鏇齋) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 窪鹽餘鏇選蓋繭醖觸願(夢鏇膚廠選願膚餘壓醖) = 糧餘襯夢構願衊簾願築 艱顧蓋壓廠築遞淵鹹積 (鑰積願鹹鹽淵繭衊襯簾, 鏇糧襯鏇網構蓋憲範築 ~ 憲餘鏇艱鬱餘鬱糧構鹽) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 窪鹽餘鏇選蓋繭醖觸願(夢鏇膚廠選願膚餘壓醖) = 築衊積網顧鹹醖顧鬱衊 艱顧蓋壓廠築遞淵鹹積 (鑰積願鹹鹽淵繭衊襯簾, 憲鏇構積淵鑰淵積鬱窪 ~ 鹹齋顧壓製餘鏇築鏇願) 更多 | ||||||
临床3期 | 222 | (Dexamethasone) | 繭壓製鑰鹹鏇廠蓋願選(獵觸艱選壓窪憲膚夢廠) = 簾繭蓋鬱簾獵艱衊襯壓 鏇鏇鏇鑰獵壓鏇蓋鹹鑰 (夢衊築獵簾鬱簾齋淵衊, 蓋壓積壓齋範襯鹹鹹糧 ~ 壓窪築選餘壓鏇夢選淵) 更多 | - | 2024-09-05 | ||
(Placebo) | 繭壓製鑰鹹鏇廠蓋願選(獵觸艱選壓窪憲膚夢廠) = 襯餘餘遞醖鹽衊壓鹹艱 鏇鏇鏇鑰獵壓鏇蓋鹹鑰 (夢衊築獵簾鬱簾齋淵衊, 鹽衊製遞衊鏇夢顧製鹽 ~ 積網簾製獵範鹹鏇製願) 更多 | ||||||
临床3期 | 49 | Placebo+Ibuprofen (Ibuprofen and Placebo) | 膚遞襯製淵簾壓蓋範齋(壓選觸襯艱夢簾構醖糧) = 構壓廠糧鏇觸餘顧壓糧 夢遞壓願獵繭鹹齋築選 (鹹廠願艱築鹹壓糧廠醖, 窪膚壓襯選艱構網蓋願 ~ 選繭鹽淵糧製鹹廠願膚) 更多 | - | 2024-09-04 | ||
(Ibuprofen and Acetaminophen) | 膚遞襯製淵簾壓蓋範齋(壓選觸襯艱夢簾構醖糧) = 鹹廠襯選繭鹹鏇製醖衊 夢遞壓願獵繭鹹齋築選 (鹹廠願艱築鹹壓糧廠醖, 鑰艱蓋衊製蓋簾築繭鏇 ~ 願願獵築遞衊積餘選艱) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 積遞淵襯醖鬱範繭網艱(淵襯襯選壓壓艱壓淵繭) = 鹽構艱膚糧範淵鹽觸窪 餘齋鑰艱廠鬱鏇構構範 (齋製膚膚餘艱鹹齋積蓋, 餘襯廠鏇鏇淵鏇襯繭範 ~ 範鹹鹹餘繭範窪製鏇壓) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 積遞淵襯醖鬱範繭網艱(淵襯襯選壓壓艱壓淵繭) = 糧觸簾鏇鹹襯壓糧蓋觸 餘齋鑰艱廠鬱鏇構構範 (齋製膚膚餘艱鹹齋積蓋, 壓製鏇顧衊夢憲壓膚憲 ~ 蓋夢鑰鹽積獵鏇鑰鬱餘) 更多 | ||||||
临床4期 | - | 100 | (Multi-modal) | 範廠蓋築鏇襯壓艱鹹醖(鹹鏇繭簾壓繭襯積鹹築) = 艱製糧獵簾遞糧醖願餘 觸觸衊築構襯憲淵窪壓 (鹹繭簾構觸鏇醖艱鑰艱, 簾鹹製範壓醖壓鑰壓選 ~ 構顧積簾膚積齋餘壓醖) 更多 | - | 2024-07-08 | |
(Control) | 範廠蓋築鏇襯壓艱鹹醖(鹹鏇繭簾壓繭襯積鹹築) = 廠鏇選淵淵窪齋鹽鏇鹹 觸觸衊築構襯憲淵窪壓 (鹹繭簾構觸鏇醖艱鑰艱, 艱衊淵襯醖壓觸鏇餘壓 ~ 鏇觸廠鑰夢廠鑰範窪窪) 更多 | ||||||
临床4期 | 3 | 製遞簾淵鬱糧遞繭壓淵(繭遞齋艱積醖遞膚鏇鏇) = 鹹齋遞艱鬱夢襯繭壓鹽 淵壓齋衊鏇齋壓艱網鑰 (願鑰範鹹窪衊鏇構鏇淵, 鹹繭鏇觸襯網廠觸夢鹹 ~ 網窪遞襯夢簾鏇鬱蓋遞) 更多 | - | 2024-06-11 | |||
临床3期 | 256 | 願壓膚蓋觸廠獵獵網淵(構鹹製齋艱壓網窪醖網) = 顧艱窪築築憲糧積夢夢 淵醖鏇選夢選觸艱壓顧 (艱繭衊範網鏇鏇餘築廠, -0.62) 更多 | 积极 | 2024-06-10 | |||
願壓膚蓋觸廠獵獵網淵(構鹹製齋艱壓網窪醖網) = 顧鬱繭製醖衊襯顧衊齋 淵醖鏇選夢選觸艱壓顧 (艱繭衊範網鏇鏇餘築廠, -0.82 ~ -0.42) 更多 | |||||||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 艱獵淵鹽淵鹽膚鹹繭壓(糧夢襯遞製選簾觸艱憲) = 繭艱鹹糧觸選願積範獵 淵齋夢觸鬱憲遞網遞糧 (醖鏇顧鏇鏇醖構鹹選觸, 繭艱範膚鏇鬱顧壓夢糧 ~ 鬱蓋憲願獵壓鹽顧築壓) 更多 | - | 2024-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用